Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
CROI 2008: Boston, Massachussetts; February 3-6, 2008

Key Links:

By Topic:

Search:

  • Email Email
  • Glossary Glossary


The 15th Conference on Retroviruses and Opportunistic Infections
BOSTON, MASSACHUSETTS
FEBRUARY 3-6, 2008

Featured Coverage

Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds
One of the most talked-about studies presented at CROI 2008, the new D:A:D findings focus on the impact of specific antiretrovirals on heart attack risk in HIV-infected patients. Jens Lundgren, M.D., Chief Physician and Director of the Copenhagen HIV Programme, summarizes the data and discusses the ramifications of the results.

Read Transcript  Listen (30 min.)More Research
Jens Lundgren, M.D.

HIV Treatment/Complications
HIV/Hepatitis Coinfection

Wafaa El-Sadr, M.D.CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc
Sarah Pett, M.D., of the University of South Wales in Australia, reviews phase 1 trial results on SCH532706; Barry Zingman, M.D., of Montefiore Medical Center in New York, discusses 48-week results from a study on vicriviroc.


More Highlights:

Megan CraneImmune Reconstitution May Trigger Hepatic Flares in HIV/Hepatitis B Coinfected Patients Starting HAART
Megan Crane, of Monash University in Melbourne, Australia, explores the immunopathogenesis of hepatic flares following the initiation of HAART with anti-hepatitis B activity in patients who are coinfected with HIV and hepatitis B.


More Highlights:

Developing World
HIV Prevention

Rebecca Bunnell, Sc.D.HAART Use Enlivens Sex Lives of Rural Ugandans, But Does Not Increase Risky Behavior, Study Says
Rebecca Bunnell, Sc.D., discusses the impact of antiretroviral use on the sexual behavior and HIV risk activities of HIV-infected people in rural Uganda.


More Highlights:

Connie Celum, M.D.Surprisingly, Acyclovir for HSV-2 Treatment Fails to Curtail HIV Acquisition
Connie Celum, M.D., discusses unexpectedly disappointing results from a study examining whether the use of acyclovir to treat herpes simplex virus type-2 infection can, in turn, help reduce a person's risk of HIV acquisition.


More Highlights:


About This Conference

The Body's coverage of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on CROI 2008, please visit the conference's Web site. You may also view the conference program online.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories.


This coverage was provided by The Body. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

  • Email Email
  • Glossary Glossary


Advertisement